Pharmacologic properties of the new oral anticoagulants: a clinician-oriented review with a focus on perioperative management.
about
Safety of new oral anticoagulant drugs: a perspectiveAnticoagulation drug therapy: a reviewAdverse safety events in patients with Chronic Kidney Disease (CKD).Hemostats, sealants, and adhesives III: a new update as well as cost and regulatory considerations for components of the surgical toolbox.Synthesis and biochemical evaluation of triazole/tetrazole-containing sulfonamides against thrombin and related serine proteases.Management of non-vitamin K antagonist oral anticoagulants in the perioperative settingApproach to the new oral anticoagulants in family practice: part 1: comparing the options.Approach to the new oral anticoagulants in family practice: part 2: addressing frequently asked questionsDabigatran in patients with atrial fibrillation: perioperative and periinterventional management.My Patient Taking A Novel Oral Anticoagulant Needs Surgery, Device Implantation, Or Ablation.Economic impact of venous thromboembolism after hip and knee arthroplasty: potential impact of rivaroxaban.Hospital-based clinical implications of the novel oral anticoagulant, dabigatran etexilate, in daily practice.Healthcare burden associated with the post-thrombotic syndrome and potential impact of the new oral anticoagulants.New anticoagulants: A concise review.Practical issues, limitations, and periprocedural management of the NOAC's.Dabigatran: is there a role for coagulation assays in guiding therapy?Rivaroxaban: practical considerations for ensuring safety and efficacy.Perioperative management of patients who are receiving a novel oral anticoagulant.New oral anticoagulants in practice: pharmacological and practical considerations.Perioperative management of oral anticoagulants: a focus on target-specific oral anticoagulants.Novel Oral Anticoagulants in Atrial Fibrillation: Update on Apixaban.Practical management of patients on apixaban: a consensus guide.A practice tool for the new oral anticoagulants.Cost-effectiveness of prevention and treatment of VTE.Influence of Body Mass Index on the Activated Clotting Time Under Weight-Based Heparin Dose.Correlation between Rs2108622 Locus of CYP4F2 Gene Single Nucleotide Polymorphism and Warfarin Dosage in Iranian Cardiovascular Patients.[Perioperative handling of anticoagulation].
P2860
Q27016072-B896DC87-6952-48A6-8D33-4BFD24CD8754Q27021871-8D581684-41E4-465C-A5E1-A9F8B458E4E0Q30245199-A32AF365-0BE4-4E24-BEF5-556D2636F416Q30455518-0505B0F8-3068-407A-BFEF-9CD211EF773CQ33977957-D63EA6CC-AA78-4502-8284-7A876E817D2DQ34207558-36356939-A8FF-4709-BBDD-86EBD1C0E134Q34497581-429DB903-050B-4B03-A709-164C540691CDQ34666269-24490B32-436D-4374-9EEE-D25939AD3D3DQ36025096-6513D383-7125-4E10-A931-D0C4D901F2CAQ37115545-2A623CAF-DAE9-4664-8C05-4327D3E8E2A8Q37889269-F01583D9-CE38-4887-AA98-7C3BCD352CDBQ37924500-6948AB23-57EA-4D5F-935E-F3007C2437F5Q37955199-FEAE5E65-2D47-4CCE-A3D7-25F0230A112AQ38043378-70879A53-7BB2-4850-9B5C-AFF3D6332D83Q38093434-0EF73F66-C06D-47DD-9B41-DD66E5E8DE23Q38106833-EDD8EA6B-5852-42B1-9E74-73A50FBB0F86Q38109840-4579BD83-0608-4D4F-BE72-692BF263BE61Q38117546-61B4DC34-312C-4BCF-9159-F0D924831832Q38180988-A539D08D-556C-471A-AD5E-D3078885EBB7Q38254247-43EB044B-0DBF-4DD5-B543-534EFBDF7CD8Q38838530-7852B623-2C58-417E-9FE9-69F79F3D01C6Q41890211-6EB73688-AD43-4500-A527-C9667FA5DB1AQ41903448-5E98B12B-AA98-409B-AE67-030860352909Q44240451-15BC12E9-CCB0-45E4-A699-1C5A502DDEF0Q47424028-BC119D2F-D397-40D7-AD13-90D3FE124B4AQ49892570-18851950-F1EE-4389-8E1E-3FFF50B08BA2Q50098495-584537A4-937D-4DD9-A8FB-7F219C7F82C3
P2860
Pharmacologic properties of the new oral anticoagulants: a clinician-oriented review with a focus on perioperative management.
description
2010 nî lūn-bûn
@nan
2010 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2010 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
name
Pharmacologic properties of th ...... s on perioperative management.
@ast
Pharmacologic properties of th ...... s on perioperative management.
@en
Pharmacologic properties of th ...... s on perioperative management.
@nl
type
label
Pharmacologic properties of th ...... s on perioperative management.
@ast
Pharmacologic properties of th ...... s on perioperative management.
@en
Pharmacologic properties of th ...... s on perioperative management.
@nl
prefLabel
Pharmacologic properties of th ...... s on perioperative management.
@ast
Pharmacologic properties of th ...... s on perioperative management.
@en
Pharmacologic properties of th ...... s on perioperative management.
@nl
P1476
Pharmacologic properties of th ...... s on perioperative management.
@en
P2093
James D Douketis
P304
P356
10.2174/138161210793563338
P577
2010-01-01T00:00:00Z